RESUMEN

Objetivos. Establecer el gasto farmacológico generado por la gonartrosis (GN) en un centro de salud urbano de atención primaria, así como los principales fármacos usados en su tratamiento y su contribución al gasto total de cada grupo estudiado. Pacientes y método. Se contabilizaron los envases consumidos durante un año de los distintos fármacos asignados a cada paciente. Se halló la media de coste de cada especialidad y se calculó el total anual. Se halló el cociente entre el gasto total y el número de pacientes, obteniéndose el gasto paciente/año. Estudio descriptivo transversal sobre una muestra de 188 pacientes diagnosticados de gonartrosis. Resultados. Los antiinflamatorios no esteroideos (AINE) fueron los fármacos más recetados y los que más gasto generaron. Los symptomatic slow-acting drug for osteoarthritis (SYSADOA) fueron los segundos en frecuencia y en gasto. El paracetamol ocupó tercer lugar. Los tratamientos tópicos, «otros analgésicos» y los inhibidores de la bomba de protones (IBP) supusieron un gasto mucho menor. El gasto total farmacológico por paciente y año fue de 151,6 € (DE:±101,9). Conclusiones. El gasto farmacéutico en la gonartrosis contribuye al aumento del coste de los recursos sanitarios en atención primaria. El coste farmacológico total por paciente y año fue de 151,60 €. La prescripción de los AINE en nuestro centro es la mayor contribución del gasto por fármacos en el tratamiento de la gonartrosis (AU)

Objective. To establish the pharmacological cost incurred by an urban Primary Health Care centre for treating osteoarthritis (OA) of the knee, including the main drugs used in its treatment and its contribution to the total cost of each group studied. Patients and methods. A cross-sectional, descriptive study of 188 patients diagnosed with OA of the knee. After counting the total number of pre-packaged pharmaceutical products assigned to each patient over one year, the average cost of each product was calculated. The ratio between the total cost and the total number of patients was then calculated, which gave the cost per patient per year. Results. NSAIDs (non-steroids anti-inflammatory drugs) were the most frequently prescribed. SYSADOAs (symptomatic slow-acting drugs for osteoarthritis) rated second in both frequency and cost. Acetaminophen rated third. Topical treatments, "other analgesics" and proton pump inhibitors (PPIs), cost much less. The total pharmacological cost per patient per year thus amounted to 151.6 € (SD:±101,9). Conclusions. The pharmacological cost for treatment of osteoarthritis of the knee incurs an increase in cost of health resources in Primary Care. The total pharmacological cost per patient per year was 151.60 €. In our centre, NSAIDs account for most of the pharmacological costs in the treatment of osteoarthritis of the knee (AU)

Asunto(s)

RESUMEN

OBJECTIVE: To establish the pharmacological cost incurred by an urban Primary Health Care centre for treating osteoarthritis (OA) of the knee, including the main drugs used in its treatment and its contribution to the total cost of each group studied. PATIENTS AND METHODS: A cross-sectional, descriptive study of 188 patients diagnosed with OA of the knee. After counting the total number of pre-packaged pharmaceutical products assigned to each patient over one year, the average cost of each product was calculated. The ratio between the total cost and the total number of patients was then calculated, which gave the cost per patient per year. RESULTS: NSAIDs (non-steroids anti-inflammatory drugs) were the most frequently prescribed. SYSADOAs (symptomatic slow-acting drugs for osteoarthritis) rated second in both frequency and cost. Acetaminophen rated third. Topical treatments, "other analgesics" and proton pump inhibitors (PPIs), cost much less. The total pharmacological cost per patient per year thus amounted to 151.6 € (SD:±101,9). CONCLUSIONS: The pharmacological cost for treatment of osteoarthritis of the knee incurs an increase in cost of health resources in Primary Care. The total pharmacological cost per patient per year was 151.60 €. In our centre, NSAIDs account for most of the pharmacological costs in the treatment of osteoarthritis of the knee.

Asunto(s)

RESUMEN

Objetivo. Conocer el gasto médico generado por la gonartrosis en atención primaria en nuestro medio, referido a consultas, pruebas complementarias e incapacidad laboral de tipo transitorio (IT). Pacientes y método. Estudio descriptivo transversal en un CAP urbano en el año 2007, sobre una muestra de 206 pacientes diagnosticados de gonartrosis según los criterios del ACR. Pacientes y método. Los costes directos médicos se estimaron de acuerdo con el valor económico asignado a los servicios sanitarios en el DOG (Diario Oficial de Galicia), y las tarifas de la Sociedad Española de Biopatología Clínica. Los costes indirectos se estimaron mediante el método del capital humano, considerando como costes los salarios correspondientes a los días de trabajo perdidos. Resultados. El número total anual de consultas, analíticas y radiografías fue de 1.003, 285 y 564 respectivamente. El total días en situación de IT al año fue de 2.675. El gasto medio «paciente/año» por consultas, analíticas y radiografías fue de 129,02 € (DE: 108), 18,59 € y 75,51 € (DE: 23), respectivamente. Los gastos generados por IT ascendieron a 577,85 € (DE: 2.750) por paciente y año. Conclusiones. El mayor gasto correspondió a la IT que representó casi las 3/4 partes del gasto anual por gonartrosis (AU)

Objective. To know the medical cost generated by osteoarthritis (OA) of the knee in Primary Care in reference to clinical visits, complementary tests and temporary work disability. Patients and methods. A cross-sectional, descriptive study of 206 patients in an urban Primary Care Center in the year 2007 diagnosed of OA according to the American College of Rheumatology (ACR) classification. Patients and methods. Direct medical costs were calculated according the list of prices assigned to the health care services by the Galician Health Administration and Spanish Society of Clinical Biopathology. Indirect costs were calculated using the human capital method, considering costs as the wages corresponding to the lost work days. Results. The total annual number of clinical visits, laboratory tests and X-rays was 1003, 285 and 564, respectively. Total days lost by temporary work disabilities were 2675 days/year. Average cost “patient/year” due to clinical visits, laboratory tests and X-rays was 129.02 € (SD: 108), 18.59 € and 75.51 € (SD: 23), respectively. Cost due to job absences was 577.85 € patient/year (SD: 2750). Conclusions. The greatest cost corresponded to temporary work disabilities, this representing almost 3/4th of the total annual cost (AU)

Asunto(s)

RESUMEN

OBJECTIVE: To test the hypothesis that joint hyperlaxity can play some role in the pathogenesis of pain in primary fibromyalgia. METHODS: A total of 66 women with fibromyalgia (according to the 1990 American College of Rheumatology criteria) and 70 women with other rheumatic diseases were examined for joint laxity based on 5 criteria (The Non-Dominant Spanish modification). Individuals meeting 4 or 5 criteria were considered to be hyperlax. RESULTS: Joint hyperlaxity was detected in 18 (27.3%) of the patients with fibromyalgia and 8 (11.4%) of those with another rheumatic disorder. The statistical analysis revealed significant differences (P < 0.05) between both groups. CONCLUSION: The results of this study suggest that joint hypermobility and fibromyalgia are associated. Joint hyperlaxity may play a prominent role in the pathogenesis of pain in fibromyalgia.

Asunto(s)

Asunto(s)

Asunto(s)

RESUMEN

A total of 675 male soldiers of the same age (17 years) and on the same physical exertion regimen were studied in order to determine the incidence of joint laxity and its potential relationship to the appearance of musculoligamentous lesions. They were investigated during their 2-month military training period, which involved the same heavy physical exertion for all the individuals. The degree of joint laxity was determined on the basis of five criteria involving the hand, elbow, knee and spine. The overall population was divided into three groups according to the number of criteria met, namely: (1) normal or non-lax individuals, with none or only one criterion (67% of the studied population); (2) lax individuals, with two or three criteria (25.5%); and (3) hyperlax individuals, with four or five criteria (7.5%). The occurrence of musculoligamentous lesions during the 2-month study, particularly those involving the ankle and knee, was significantly more frequent in hyperlax and lax individuals than it was in their counterparts with normal joint mobility. These results confirm that joint hyperlaxity predisposes individuals to musculoligamentous lesions.

Asunto(s)